Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 6/20 | 1.00 |
| ▸ | NT5E | P21589 | 5/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 1/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.86 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.83 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.81 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.81 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.81 |
| ▸ | LDHA | P00338 | 1/20 | 0.81 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.81 |
| ▸ | FBP1 | P09467 | 1/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.81 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL21067537 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL14414858 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL29394370 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL29357429 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL16351400 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL24205127 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL4314227 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| Phosphomethylphosphonic Acid Adenosyl Ester SCHEMBL21724956 | 1.00 | ENPP1 (1.00) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| SCHEMBL16674879 | 0.96 | ENPP1 (0.92) | ENPP1NT5EPLCG1P2RX1P2RX3 | |
| SCHEMBL18351578 | 0.96 | ENPP1 (0.92) | ENPP1NT5EPLCG1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3789403-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND A2A RECEPTOR INHIBITOR AND USES THEREOF | MedImmune Limited (GB) | 2021-03-10 | — | — | EP | disclosed |
| US-10864269-B2 | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2020-12-15 | — | — | US | disclosed |
| US-20180125973-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| WO-2017207690-A1 | PROGNOSTIC RELEVANCE OF MIR-422A IN HEAD AND NECK SQUAMOUS CELL CARCINOMA | Centre Léon-Bérard (FR) | 2017-12-07 | — | — | WO | disclosed |
| EP-3218407-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND A2A RECEPTOR INHIBITOR AND USES THEREOF | Medimmune Limited (GB) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075176-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND A2A RECEPTOR INHIBITOR AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-05-19 | — | — | WO | disclosed |
| US-20160129108-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864269-B2 | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | ENTPD5, NT5E, ADORA2A | ENPP1 72/4885NT5E 2/4885PLCG1 713/4885 |
| US-20160129108-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF | ENTPD5, NT5E, ADORA2A | ENPP1 72/4885NT5E 2/4885PLCG1 713/4885 |
| US-20180125973-A1 | THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF | ENTPD5, NT5E, ENTPD1 | ENPP1 49/4885NT5E 2/4885PLCG1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.